Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | THZ1 |
| Synonyms | |
| Therapy Description |
THZ1 is a covalent Cdk7 inhibitor that inhibits tumor cell proliferation (PMID: 25043025, PMID: 32690037). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| THZ1 | HY-80013|THZ-1 | CDK7 Inhibitor 16 | THZ1 is a covalent Cdk7 inhibitor that inhibits tumor cell proliferation (PMID: 25043025, PMID: 32690037). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK | lung adenocarcinoma | sensitive | THZ1 | Preclinical - Cell culture | Actionable | In a preclinical study, THZ1 treatment reduced viability and inhibited proliferation of parental lung adenocarcinoma, and isogenic cells resistant to Xalkori (crizotinib), Zykadia (ceritinib), and Alecensa (alectinib) cells, all harboring EML4-ALK, in culture (PMID: 32558295). | 32558295 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|